Search

Your search keyword '"Abdelnour, C."' showing total 106 results

Search Constraints

Start Over You searched for: Author "Abdelnour, C." Remove constraint Author: "Abdelnour, C."
106 results on '"Abdelnour, C."'

Search Results

1. Evaluation of the Feasibility, Safety and Efficacy of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in People Affected by Moderate to Severe Alzheimer’s Disease: A Double-Blind Masked Clinical Trial for Dose Finding

2. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

3. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (Nature Communications, (2021), 12, 1, (3417), 10.1038/s41467-021-22491-8)

4. Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results

5. New insights into the genetic etiology of Alzheimer's disease and related dementias

6. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

7. Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia

8. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

9. 21447. EFECTO DE LA PATOLOGÍA ALZHEIMER EN EL FENOTIPO NEUROPSICOLÓGICO DE PACIENTES CON ENFERMEDAD CON CUERPOS DE LEWY

10. New insights into the genetic etiology of Alzheimer's disease and related dementias

11. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

12. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

13. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

14. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

15. The combined effect of amyloid-beta and tau biomarkers on brain atrophy in dementia with Lewy bodies

16. CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies

17. The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE ¿4 Non-carriers

18. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

19. GBA and APOE epsilon 4 associate with sporadic dementia with Lewy bodies in European genome wide association study (vol 9, 7013, 2019)

20. The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE epsilon 4 Non-carriers

21. Combination of white matter hyperintensities and Aβ burden is related to cognitive composites domain scores in subjective cognitive decline: the FACEHBI cohort.

22. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

23. Exploring APOE genotype effects on Alzheimer's disease risk and amyloid beta burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results

24. Long runs of homozygosity are associated with Alzheimer's disease.

25. Biomarcadores en sangre para la enfermedad de Alzheimer: posicionamiento y recomendaciones de uso del Grupo de Estudio de Conducta y Demencias de la Sociedad Española de Neurología

26. FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLS

27. Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia

28. Guia d’abordatge del delírium

29. Patients with dementia with Lewy bodies display a signature alteration of their cognitive connectome.

30. 18 F-PI-2620 Tau PET is associated with cognitive and motor impairment in Lewy body disease.

31. What is the future for dementia with Lewy bodies?

32. Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease.

33. The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.

34. Decentralized clinical trials for medications to reduce the risk of dementia: Consensus report and guidance.

35. Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for Clinicians.

36. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra.

37. Correction: Ethical challenges of using remote monitoring technologies for clinical research: A case study of the role of local research ethics committees in the RADAR-AD study.

38. Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers.

39. Ethical challenges of using remote monitoring technologies for clinical research: A case study of the role of local research ethics committees in the RADAR-AD study.

40. Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022.

41. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress.

42. Cognitive Impairment in Neurodegenerative Movement Disorders.

43. Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design.

44. Introducing CARESSER: A framework for in situ learning robot social assistance from expert knowledge and demonstrations.

45. Perspectives and challenges in patient stratification in Alzheimer's disease.

46. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type.

47. Alzheimer's disease diagnosis and management: Perspectives from around the world.

48. Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data.

49. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.

50. Neuropsychiatric Profile as a Predictor of Cognitive Decline in Mild Cognitive Impairment.

Catalog

Books, media, physical & digital resources